https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53837 Wed 28 Feb 2024 15:17:37 AEDT ]]> Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19379 Wed 11 Apr 2018 14:19:24 AEST ]]> Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28241 Wed 11 Apr 2018 10:43:55 AEST ]]> Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20763 Wed 11 Apr 2018 09:54:54 AEST ]]> Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51614 Tue 12 Sep 2023 13:49:19 AEST ]]> Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24206 Thu 04 Nov 2021 10:38:26 AEDT ]]> Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19000 Sat 24 Mar 2018 08:05:34 AEDT ]]> Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49499 Fri 19 May 2023 12:01:55 AEST ]]> Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41264 vs 165 cases, hazard ratio [HR] 0·51, 95% CI 0·39–0·66, p<0·0001). The reduction was larger in the first 5 years (35 vsvsvs 70, HR 0·96, 95% CI 0·69–1·34, p=0·82) or for breast cancer (two anastrozole vs three placebo). A significant decrease in non-breast cancers was observed for anastrozole (147 vs 200, odds ratio 0·72, 95% CI 0·57–0·91, p=0·0042), owing primarily to non-melanoma skin cancer. No excess of fractures or cardiovascular disease was observed. Interpretation: This analysis has identified a significant continuing reduction in breast cancer with anastrozole in the post-treatment follow-up period, with no evidence of new late side-effects. Further follow-up is needed to assess the effect on breast cancer mortality.]]> Fri 11 Aug 2023 16:56:23 AEST ]]>